Smaller Insulin Pump Gets New Clinical Leader

People using automated insulin pumps may see a half-size, app-controlled option as MiniMed adds David Segal, M.D., as CMO.

Updated on Nov. 4, 2026 in Diabetes

Bold flat-color vector editorial illustration of a small rounded insulin pump in pale teal and white, alone on a warm cream background with a coral tubing loop.
MiniMed named David Segal, M.D., its chief medical officer, succeeding Robert Vigersky, M.D., who will retire at the end of 2027. AI Illustration. Upload story photo >

MiniMed has named David Segal, M.D., its chief medical officer, succeeding Robert Vigersky, M.D., who moves to chief medical officer emeritus ahead of his planned retirement at the end of 2027. Segal brings more than 20 years of experience in diabetes care, digital health, and healthcare innovation to the insulin-pump maker.

Why it matters

Leadership in a diabetes device company shapes how insulin pumps are designed, studied, and supported for the people who wear them. The change comes as MiniMed expands its product line and operates as an independent company following its recent separation from Medtronic.

This is a corporate announcement rather than a clinical study, so no trial or cohort results are reported. The figures cited are company-reported financial and regulatory milestones, including the $560 million IPO proceeds and the roughly half-size comparison between the MiniMed Flex and the 780G pump.

The players

MiniMed

A diabetes technology company that makes insulin pumps and automated insulin delivery systems, including the MiniMed Flex and the 780G.

David Segal, M.D.

A diabetes and digital health physician with more than 20 years of experience, who co-founded the telecoaching company Guidepost.

Robert Vigersky, M.D.

A diabetes physician who has served as MiniMed's chief medical officer since 2019 and is moving to emeritus status ahead of retirement.

The details

The MiniMed Flex is controlled through a compatible smartphone app rather than an onboard screen, and it uses the SmartGuard algorithm to automatically adjust insulin delivery based on glucose readings. Its smaller footprint, roughly half the size of the 780G pump cleared in 2023, reflects the company's effort to make automated insulin delivery less cumbersome to wear. Segal previously led medical innovation and remote monitoring work at Parkview Health's Mirro Center and helped establish a pediatric endocrinology service there.

Timeline

  1. Vigersky became chief medical officer in 2019 and will retire at the end of 2027.

  2. MiniMed Flex received FDA clearance in March 2026.

  3. MiniMed closed its Nasdaq IPO on March 9, 2026.

  4. MiniMed completed its separation from Medtronic on October 15, 2026.

Health Landscape

The MiniMed Flex builds on the 780G, cleared by the FDA in 2023, by offering a pump about half that size controlled through a smartphone app. The change reflects a broader push in diabetes care toward smaller, app-managed automated insulin delivery systems.

If you use or are considering an insulin pump, the MiniMed Flex offers a smaller, app-controlled option worth discussing with your diabetes care team. Any change in device should be a conversation with your physician, since pump suitability depends on individual needs.

The takeaway

Leadership and product changes at device makers can shape the tools people with diabetes use every day. If you wear an insulin pump, ask your care team whether a newer, smaller model could fit your routine.

Further reading

For more on how these devices fit into care, explore our Diabetes coverage.